<DOC>
	<DOCNO>NCT00510614</DOCNO>
	<brief_summary>This research study do evaluate use oral ( mouth ) medication call tinidazole initially treat BV see additional treatment tinidazole keep woman get infection back within 3 month . Tinidazole currently approve United States Food Drug Administration ( FDA ) treat bacterial vaginosis ( BV ) . This study evaluate use tinidazole treat woman 's current BV infection look use tinidazole suppressive treatment ( take medication regularly attempt decrease `` bad '' bacteria grow back ) . The suppressive treatment phase include use tinidazole twice week compare use placebo twice week follow woman recurrence BV . The purpose study determine tinidazole suppression prevent BV come back within 3 month treatment . The investigator hypothesize woman history recurrent bacterial vaginosis randomize suppressive regimen ( dose medication give regular basis attempt control bacteria cause bacterial vaginosis ) tinidazole low recurrence rate long time recurrence bacterial vaginosis compare woman randomize placebo .</brief_summary>
	<brief_title>Tinidazole Recurrent Bacterial Vaginosis : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Tinidazole</mesh_term>
	<criteria>1 . Age 1845 time enrollment . 2 . Recurrent BV define : 2 previously document diagnosis BV past 6 month 3 previously document diagnosis BV past year 3 . Nonpregnant , nonlactating . 4 . Premenopausal . 5 . Presence bacterial vaginosis enrollment visit use Amsel Criteria ( least 3 4 ) : Presence homogenous vaginal discharge pH vaginal secretion &gt; 4.7 Presence positive `` whiff '' test vaginal secretion upon mix 10 % KOH Presence &gt; 20 % clue cell saline microscopy 6 . Willingness undergo randomization possible placebo arm ( suppressive therapy ) . 7 . Ability undergo inform consent . 8 . Willingness refrain use intravaginal product ( include douching , contraceptive spermicide , cream , gel , foam ) . 9 . Currently use acceptable method birth control ( hormonal method include oral contraceptive , Depo Provera , Ortho Evra , abstinence x 60 day , consistent condom use , surgically sterile , lesbian orientation ) . 10 . Willing refrain alcohol consumption use study medication three day follow completion medication ( include 10 day open label treatment entire 3 month suppressive phase treatment ) . 1 . Known active sexually transmit infection time enrollment C. trachomatis , N. gonorrhoeae , T. vaginalis , active ( symptomatic ) vulvovaginal candidiasis . 2 . Current use anticoagulants/blood thinner ( i.e . warfarin , coumadin , heparin ) . 3 . Current use follow medication : lithium , fluorouracil , anticonvulsant/seizure medication , Questran ( cholestyramine ) CYP3A4 inducer/inhibitors ( i.e . phenobarbital , rifampin , phenytoin , fosphenytoin ) . 4 . Use Antabuse ( disulfiram ) currently within past 2 week . 5 . Allergy metronidazole tinidazole ( relate drug likely crossover allergy potential ) . 6 . Use antibiotic ( oral vaginal ) past 7 day . 7 . Current use IUD , Nuva Ring . 8 . Known immunosuppressive condition ( i.e . HIV , endstage renal disease , currentlytreated diabetes mellitus , etc . ) immunosuppressive medication [ i.e . steroid , cyclosporine , Protopic ( tacrolimus ) , immunomodulators ] . 9 . Participation investigational drug study within past 30 day . 10 . Any condition opinion investigator would impose health risk subject interfere evaluation study medication procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Bacterial Vaginosis</keyword>
	<keyword>Recurrent Bacterial Vaginosis</keyword>
</DOC>